Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
GKOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$77.10 - $163.71
Previous CloseN/A
Volume137.72K
Average Volume (3M)794.24K
Market Cap
$4.97B
Enterprise Value$5.74B
Total Cash (Recent Filing)$274.79M
Total Debt (Recent Filing)$105.02M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Oct 29, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding57,349,987
10 Day Avg. Volume779,372
30 Day Avg. Volume794,235
Financial Highlights & Ratios
PEG Ratio150.23
Price to Book (P/B)10.31
Price to Sales (P/S)20.63
P/FCF Ratio-116.98
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue13.26
Enterprise Value/Gross Profit17.36
Enterprise Value/Ebitda-92.29
Forecast
1Y Price Target
$117.08Price Target Upside39.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Market OpportunityKeratoconus impacts about 600,000 people annually, representing a significant market opportunity for GKOS estimated at approximately $3 billion.
Product AdoptionEpioxa does not require the removal of the corneal epithelium, leading to a faster recovery and procedure time, which could drive higher adoption rates.
Reimbursement ProgressNGS is the third largest Medicare Administrator Contractor in the U.S., and its posting of physician fee amounts for iDose is a positive update for GKOS.
Bears Say
Guidance DisruptionThere are some notable headwinds implied in the more modest guidance increase including a Photrexa-to-Epioxa transition in 4Q25 that is likely to cause disruption.
Market CompetitionA slowdown in the OUS glaucoma segment is observed, attributed to ongoing competitive trialing.
Segment WeaknessThe company is experiencing continued weakness from the U.S. glaucoma segment due to ongoing challenges.
Glaukos News
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $77.10 and its highest was $163.71 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $4.97B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Oct 29, 2025 which is in 20 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Jul 30, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.264 by $0.024.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.26.
How many shares outstanding does Glaukos have?
Glaukos has 57,349,987 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.264. Following the earnings report the stock price went down -8.464%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
Glaukos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.08 (39.23% Upside)
$117.08 (39.23% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 79.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.48%
12-Months-Change
Fundamentals
Return on Equity
-12.98%
Trailing 12-Months
Asset Growth
7.32%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
GKOS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with record sales and significant growth in key areas, particularly in the U.S. and international glaucoma franchises. However, there are notable challenges, including market turbulence from regulatory changes and proposed reimbursement reductions that could impact future growth. Overall, the highlights slightly outweigh the lowlights.View all GKOS earnings summariesGKOS Stock 12 Month Forecast
Average Price Target
$117.08
▲(39.23% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
1.16% Insiders
43.88% Mutual Funds
27.43% Other Institutional Investors
3.26% Public Companies and
Individual Investors